HORSHAM, Pa. (March 20, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and…Original Article
FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease
